Mrak, Daniel http://orcid.org/0000-0001-5321-6751
Sieghart, Daniela http://orcid.org/0000-0003-1281-2295
Simader, Elisabeth
Tobudic, Selma
Radner, Helga
Mandl, Peter
Göschl, Lisa
Koblischke, Maximilian
Hommer, Nikolaus http://orcid.org/0000-0002-4116-1359
Wagner, Angelika
Mayer, Margareta
Schubert, Lorenz
Hartl, Lukas http://orcid.org/0000-0003-3398-6120
Kozbial, Karin
Hofer, Philipp http://orcid.org/0000-0003-2550-6019
Kartnig, Felix
Hummel, Thomas
Kerschbaumer, Andreas
Deimel, Thomas
Puchner, Antonia
Gudipati, Venugopal
Thalhammer, Renate
Munda, Petra
Uyanik-Ünal, Keziban
Zuckermann, Andreas
Novacek, Gottfried
Reiberger, Thomas
Garner-Spitzer, Erika http://orcid.org/0000-0002-5283-0458
Reindl-Schwaighofer, Roman http://orcid.org/0000-0002-4419-6282
Kain, Renate http://orcid.org/0000-0002-2428-543X
Winkler, Stefan
Smolen, Josef S. http://orcid.org/0000-0002-4302-8877
Stiasny, Karin http://orcid.org/0000-0002-1902-8674
Fischer, Gottfried F.
Perkmann, Thomas
Haslacher, Helmuth
Zeitlinger, Markus
Wiedermann, Ursula
Aberle, Judith H.
Aletaha, Daniel http://orcid.org/0000-0003-2108-0030
Heinz, Leonhard X. http://orcid.org/0000-0002-6921-1493
Bonelli, Michael http://orcid.org/0000-0002-6122-7482
Funding for this research was provided by:
Medizinische Universität Wien
Provision of vaccines and laboratory testing was provided free of charge by the City of Vienna and the Medical University of Vienna via the Vienna General Hospital.
Article History
Received: 5 February 2022
Accepted: 30 August 2022
First Online: 12 September 2022
Competing interests
: P.M. reports speaker fees from AbbVie, Janssen, and Novartis and research grants from AbbVie, BMS, Novartis, Janssen, MSD, and UCB. M.B. reports about personal fees from Eli Lilly, D.A. received grants and consulting fees from AbbVie, Amgen, Lilly, Merck, Novartis, Pfizer, Roche, and Sandoz, J.S. reports about grants, consulting, and personal fees from AbbVie, Astra-Zeneca, Lilly, Novartis, Amgen, Astro, Bristol-Myers Squibb, Celgene, Celltrion, Chugai, Gilead, ILTOO, Janssen, Merck Sharp & Dohme, Novartis-Sandoz, Pfizer, Roche, Samsung, and UCB, M.Z. received grants and consulting fees from Nabriva, AntibioTxApS, Shionogi, NovoNordisk, Merck, Infectopharm, and Pfizer, H.H. received grants from Glock Health, BlueSky Immunotherapies, and Neutrolis. G.N. served as a speaker/consultant/advisory board member for AbbVie, MSD, Takeda, Janssen, Sandoz, Pfizer, Astro Pharma, Falk Pharma GmbH, Ferring, Gilead, Galapagos, and Vifor. E.S. reports support for meeting attendances from Pfizer and Bristol Myers Squibb. D.M. received support for meeting attendances from Pfizer. T.R. received grant support from Abbvie, Boehringer-Ingelheim, Gilead, Gore, Intercept, MSD, Myr Pharmaceuticals, Philips Healthcare, Pliant, and Siemens; speaking honoraria from Abbvie, Gilead, Gore, Intercept, Roche, MSD; consulting/advisory board fee from Abbvie, Bayer, Boehringer-Ingelheim, Gilead, Intercept, MSD, Siemens; and travel support from Abbvie, Boehringer-Ingelheim, Gilead, and Roche. A.K. reports about speaker and consulting fees from AbbVie, Amgen, Bristol Myers Squibb, Eli Lilly, Gilead, Janssen, Merck Sharp and Dohme, Novartis, and Pfizer. The remaining authors declare no competing interests.